Antonio Calles, Medical Oncologist at Hospital General Universitario Gregorio Marañón and faculty member of the Lung and Other Thoracic Tumours faculty group of the ESMO, shared The Lancet’s post on X, adding:
“Where is the ethical justification for offering pembrolizumab alone to patients with low PD-L1 expression in this trial?
What would these patients receive if they were not participating in the study?
Chemotherapy alone?
Thats why patients participate?
To take the chance to be assigned to the experimental arm? Unfortunately a randomized phase 3 trial with no clinical implications due to a flawed trial design.”
Quoting The Lancet’s post:
“Presented at ASCO26 – OptiTROP-Lung05 phase 3 interim analysis. The findings suggest first-line treatment with sacituzumab tirumotecan (sac-TMT) plus pembrolizumab significantly prolonged PFS vs pembrolizumab alone in patients with PD-L1-positive advanced NSCLC without targetable genomic alterations.”
Title: Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
Authors: Anwen Xiong, Wenxiu Yao, Wei Zheng, Yan Yu, Peng Chen, Hua Zhong, Junyou Ge, Hui Wang, Bolin Chen, Haiyong Wang, Yun Fan, Yunpeng Yang, Xingxiang Pu, Xia Song, Qiming Wang, Xiaobo Du, Zhangzhou Huang, Xingya Li, Hui Luo, Yu Yao, Qitao Yu, Cuiyun Su, Lang He, Guanming Jiang, Jiuwei Cui, Chunling Liu, Tienan Yi, Guowei Che, Zhentian Liu, Lemeng Zhang, Ming Zhou, Yong Fang, Youneng Wei, Yan Qing, Xiaoping Jin, Caicun Zhou
Other articles featuring Antonio Calles and The Lancet on OncoDaily.
